Rubius Therapeutics Inc RUBY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:28 PM EDT
18.34quote price arrow down-0.71 (-3.73%)
Volume
123,788
52 week range
4.20 - 38.71
Loading...
  • Open18.93
  • Day High19.00
  • Day Low18.31
  • Prev Close19.05
  • 52 Week High38.71
  • 52 Week High Date03/15/21
  • 52 Week Low4.20
  • 52 Week Low Date10/30/20

Key Stats

  • Market Cap1.646B
  • Shares Out89.77M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta2.51
  • YTD % Change143.08

KEY STATS

  • Open18.93
  • Day High19.00
  • Day Low18.31
  • Prev Close19.05
  • 52 Week High38.71
  • 52 Week High Date03/15/21
  • 52 Week Low4.20
  • 52 Week Low Date10/30/20
  • Market Cap1.646B
  • Shares Out89.77M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta2.51
  • YTD % Change143.08

RATIOS/PROFITABILITY

  • EPS (TTM)-2.08
  • P/E (TTM)-8.81
  • Fwd P/E (NTM)-7.80
  • EBITDA (MRQ)-165.603M
  • ROE (MRQ)-74.07%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)28.66%

EVENTS

  • Earnings Date11/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Rubius Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune...
David Epstein
Chairman
Pablo Cagnoni M.D.
President
Dannielle Appelhans
Chief Operating Officer
Jose Carmona
Chief Financial Officer
Address
399 Binney St Ste 300
Cambridge, MA
02142-1038
United States

Top Peers

SYMBOLLASTCHG%CHG
PRLD
Prelude Therapeutics Inc
33.04-1.41-4.09%
INO
Inovio Pharmaceuticals Inc
7.41-0.36-4.70%
REPL
Replimune Group Inc
30.38-1.92-5.94%
KDMN
Kadmon Holdings Inc
8.81-0.03-0.40%
OCGN
Ocugen Inc
7.16-0.51-6.65%